Qurient Co., Ltd.
Research Qurient Co., Ltd. (115180.KQ) on Bullrun: market cap KRW 806.87B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker115180.KQ
- ExchangeKQ
- CountrySouth Korea
- SectorHealthcare
- IndustryBiotechnology
- CurrencyKRW
- Market capKRW 806.87B
- Financial periodQ2 2026
- RevenueKRW 1.91B
- Net income-KRW 12.72B
- Free cash flow-KRW 8.17B
- Gross margin9.3%
Valuation Snapshot
latest market cap is KRW 806.87B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | KRW 806.87B | n/a | n/a | n/a |
Dividend history
About Qurient Co., Ltd.
Qurient Co., Ltd., a biotech company, engages in the research and development of drugs to address unmet medical needs in Korea and internationally. The company's pipeline products include Q301, a topical 5LO inhibitor, which is in Phase II clinical trial for the treatment of atopic dermatitis; and Telacebec (Q203), Cyt bc1 Inhibitor, that is in Phase II to treat Mycobacterial Infections, such as tuberculosis/non-TBM.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Qurient Co., Ltd.'s market cap?
Qurient Co., Ltd.'s market capitalization is KRW 806.87B.
What does Qurient Co., Ltd. do?
Qurient Co., Ltd., a biotech company, engages in the research and development of drugs to address unmet medical needs in Korea and internationally. The company's pipeline products include Q301, a topical 5LO inhibitor, which is in Phase II clinical trial for the treatment of atopic dermatitis; and Telacebec (Q203), Cyt bc1 Inhibitor, that is in Phase II to treat Mycobacterial Infections, such as tuberculosis/non-TBM.